Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 22;4(1):e318. doi: 10.1097/HS9.0000000000000318

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

PMC Copyright notice

Genomic profiling of relapsed BCP-ALL. (A) Frequency of genetic alterations in pathways studied in relapse samples. B-cell differentiation genes include IKZF1, IKZF2, IKZF3, PAX5, and EBF1. Cell cycle regulation genes include CDKN2A, CDKN2B, TP53, and RB1. Transcription regulators include CREBBP and ETV6. Ras signaling genes include KRAS, NRAS, PTPN11, FLT3, and BRAF. Drug response genes are NT5C2, BTG1, and NR3C1. Genes involved in JAK/STAT signaling are JAK1, JAK2, and JAK3. (B) Frequency of genetic alterations in the genes studied in relapse samples.